switching from insulin to glp-1 Clinical Focus on Agonists in Type 2 Diabetes Mellitus GLP-1 receptor agonists and DPP-4

After safety concerns in phase III of its GLP-1 analog taspoglutide, Roche got back into the obesity market by acquiring Carmot Therapeutics in 2024

Clients often report enhanced mental clarity, improved mood, better sleep, and increased energy after treatment

Anti-aging properties that tightens skin, smoothens wrinkles, reduce darkspots, freckles & acne scars

It carried out its own meta-analysis of 91 clinical trials across GLP-1 drug development programmes involving more than 100,000 subjects to improve its estimate of the risk, and also conducted a review of healthcare claims data to compare the risk of intentional self-harm with SGLT2 inhibitors used to treat diabetes

10.3389/fpsyt.2024.1386263 49 JosifovskaS.PanovS.Hadzi-PetrushevN.MitrokhinV.KamkinA.StojchevskiR.et al (2023)